Androgen Receptor and Apolipoprotein D in Breast Cancer
Author Information
Author(s): RE Hall, JO Aspinall, DJ Horsfall, SN Birrell, JM Bentell, RL Sutherland, WD Tilley
Primary Institution: Flinders University of South Australia
Hypothesis
The study evaluates the expression of the androgen receptor (AR) and apolipoprotein D (apo-D) in human breast cancer to understand their roles in tumor responsiveness and regulation.
Conclusion
The study found that while AR is expressed in all breast tumors evaluated, its expression does not correlate with apo-D levels, suggesting other factors regulate apo-D in primary breast cancers.
Supporting Evidence
- AR was expressed in all breast tumors evaluated.
- AR expression levels were found to be the sole predictor of response to medroxyprogesterone acetate therapy.
- Discordant staining for AR was observed in a subset of tumors, suggesting structural alterations.
Takeaway
This study looked at how a protein called the androgen receptor works in breast cancer and found that it doesn't always work the same way as another protein called apo-D.
Methodology
The study used immunohistochemistry and color video image analysis to evaluate AR and apo-D expression in breast cancer specimens.
Limitations
The study does not explore the functional significance of AR mutations or the presence of AR variants in detail.
Participant Demographics
{"age":{"median":62,"range":"31-82"},"tumor_size":{"median":24,"range":"9-50"},"involved_lymph_nodes":{"median":2,"range":"0-10"},"node_negative_percentage":56,"ER":{"median":62,"range":"0-1044"},"PR":{"median":163,"range":"0-1133"}}
Statistical Information
P-Value
p=0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website